Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients by Ghaleb Elyamany, Mohammad Awad, Kamal Fadalla, Mohamed Albalawi, Mohammad Al Shahrani, Abdulaziz Al Abdulaaly

“…The Fms-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase that plays a key role in cell survival, proliferation, and differentiation of hematopoietic stem cells. …”
Get full text

Sorafenib-Associated Heart Failure Complicated by Cardiogenic Shock after Treatment of Advanced Stage Hepatocellular Carcinoma: A Clinical Case Discussion by Candace Wu, Kamal Shemisa

“…Sorafenib, an oral tyrosine kinase inhibitor (TKI), targets multiple tyrosine kinase receptors (TKRs) involved in angiogenesis and tumor growth. …”
Get full text

Gastrointestinal stromal tumors by A. P. Seryakov

“…Diagnostics, treatment and outcome at patients with GIST underwent significant changes for last 10 years due to discovering of molecular mechanisms, resulting in development of tumor: activated mutations of KITand PDGFR α-tyrosine kinase. These findings promoted development of tyrosine kinase inhibitor – imatinib which demonstrated essential advantage in terms of survival rate of patients. …”
Get full text

Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells by Ahmad Hamad, Zeyad Sahli, Maya El Sabban, Maha Mouteirik, Rihab Nasr

“…Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. …”
Get full text

Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report by Stefanie Klampfleitner, Andreas Fertl, Ositha Prinz, Martin Doerfler-Schalm, Dieter Munker, Markus O. Henke

“…Introduction: Nintedanib is a tyrosine kinase inhibitor and has been approved for the treatment of idiopathic pulmonary fibrosis (IPF) since 2020. …”
Get full text

Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis by Mariana M. Sebastião, Rodrigo S. Ho, João Paulo V. de Carvalho, Micha Nussbaum

“…The aim of the study was to carry out a systematic review and a meta-analysis in order to determine the accuracy of NGS of ctDNA to detect six oncogenic driver alterations: epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK); ROS proto-oncogene 1, receptor tyrosine kinase (ROS-1); serine/threonine-protein kinase B-RAF (BRAF); RET proto-oncogene (RET); and MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 in patients with aNSCLC. …”
Get full text

Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer by Mikito Inokuchi, Yoshitaka Fujimori, Sho Otsuki, Yuya Sato, Masatoshi Nakagawa, Kazuyuki Kojima

“…Preclinical studies in animal models suggest that multitargeted tyrosine kinase inhibitors (TKIs), including FGFR inhibitor, suppress tumor cell proliferation and delay tumor progression. …”
Get full text

Hepatocyte Growth Factor in Synaptic Plasticity and Alzheimer's Disease by Shiv K. Sharma

“…HGF signaling, which is initiated by its binding to a receptor tyrosine kinase, plays critical roles during development. …”
Get full text

NTRK amplification occurs frequently in pan-TRK immunopositive dedifferentiated liposarcomas by Zoltán Lippai, Gergő Papp, Károly Szuhai, Johanna Sápi, Katalin Dezső, Zoltán Sápi

“…The neurotrophic tyrosine kinase receptor (NTRK) gene family is of rising importance as their fusions are oncogenic, and specific target drugs are available to inhibit the chimera proteins. …”
Get full text

Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability by Huiling Su, Jie Shen, Chenzi Gao, Yue Zhao, Wanyu Deng, Bo Qin, Xin Zhang, Juan Lai, Qian Wang, Jie Dou, Min Guo

“…Notably, mutations in the EGFR tyrosine kinase domain, which typically confer resistance to TKIs, did not alter the regulatory effect of EPN3. …”
Get full text

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece by George Gourzoulidis, Oresteia Zisimopoulou, Nadia Boubouchairopoulou, Christina Michailidi, Chrissy Lowry, Charalampos Tzanetakos, Georgia Kourlaba

“…Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of patients with advanced, ALK-positive NSCLC previously treated with at least one second-generation ALK tyrosine kinase inhibitor. **Objective:** The present study assessed the cost-effectiveness of lorlatinib vs pemetrexed with platinum combination of carboplatin or cisplatin (P-ChT) in Greece. …”
Get full text

Discovery of a Novel DYRK1A Mutation (c.524del) in Intellectual Development Disorder Autosomal Dominant 7 (MRD7): A Comprehensive Case Analysis by Fiona Whitaker, Alvaro Serrano

“…Dual-specificity tyrosine kinase 1A (DYRK1A) is a member of the CMGC family that is linked to a multitude of neuronal development pathways. …”
Get full text

Constructing adverse outcome pathway for per- and polyfluoroalkyl substances and retinoblastoma based on PI3K-AKT/MAPK signaling pathway by Yuyan GUI, Tingji WANG, Minghao WANG, Yaqi XU, Yunhui ZHANG

“…Oncogenes, including the c-kit-encoded tyrosine kinase receptor for stem cell factor, epidermal growth factor receptor, and neurotrophic tyrosine kinase receptor 1, were identified as the receptors with the best predicted binding affinity. …”
Get full text

Flt3 Regulation in the Mononuclear Phagocyte System Promotes Ocular Neovascularization by Yushuo Gao, Yisheng Zhong, Yanji Zhu, Anna M. Demetriades, Yujuan Cai, Jikui Shen, Qing Lu, Xi Shen, Bing Xie

“…Fms-like tyrosine kinase 3 (Flt3), a tyrosine kinase receptor expressed in CD34+ hematopoietic stem/progenitor cells, is important for both normal myeloid and lymphoid differentiation. …”
Get full text

A case of pityriasis rubra pilaris secondary to ponatinib by Ariana Nateghi, Florence Lagacé-Thomassin, Julie Desrochers

“…Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia and acute lymphoblastic leukemia, can cause rare cutaneous side effects. …”
Get full text

Treatment approaches in advanced penile cancer: targeted therapies and immunotherapy by David J. Benjamin, Robert C. Hsu

“…Several ongoing trials involving immune checkpoint inhibitors, tyrosine kinase inhibitors, and antibody drug conjugates are attempting to identify additional therapies.…”
Get full text

Tailored Therapy in Lung Cancer by George Rakovich, Lise Tremblay

“…Advances in molecular biology have made possible the development of drugs against specific molecular targets on cancer cells, most notably the tyrosine kinase inhibitors. The relevant literature and current practice guidelines are discussed. …”
Get full text

New Strategies and In Vivo Monitoring Methods for Stem Cell-Based Anticancer Therapies by Ping Wang, Aitor Aguirre

“…Despite significant advances in recent years, such as the introduction of targeted therapies such as receptor tyrosine kinase inhibitors and immunotherapy, current approaches are insufficient to stop the advance of the disease and many cancer types remain largely intractable. …”
Get full text

Hepatocellular carcinoma: signaling pathways and therapeutic advances by Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin

“…At present, the primary therapeutic approaches for advanced HCC are tyrosine kinase inhibitors (TKI), immune checkpoint inhibitors (ICI), and combination regimens. …”
Get full text

Squamous Cell Carcinoma of the Lung with Metastasis to the GI Tract Associated with EGFR Exon 19 Deletion by Glen J. Weiss, Agnes K. Liman, Jeffrey Allen, Philip Y. Cheung, Rajesh N. Kukunoor

“…One of these patients received EGFR tyrosine kinase directed therapy for a brief period with some symptom relief. …”
Get full text